Zobrazeno 1 - 8 of 8 pro vyhledávání: '"Grace Ulerio"'
1
An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch Type Alopecia Areata, Totalis and Universalis
Autor: Angela M. Christiano, F. Sansaricq, J. Borbon, A. Bitterman, Julian Mackay-Wiggan, Ali Jabbari, Raphael Clynes, J.C. Chen, Jane E. Cerise, Grace Ulerio
Alopecia areata (AA) is a common autoimmune disease with a lifetime risk of ∼2%. In AA, the immune system targets the hair follicle, resulting in clinical hair loss. The prognosis of AA is unpredictable, and currently there is no definitive treatme
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54990d10b94cec0dda08a2c4bbb6761a
https://europepmc.org/articles/PMC6564681/
Zobrazit plný text záznamu
2
Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
Autor: Angela M. Christiano, Roger D. Vaughan, Raphael Clynes, Ali Jabbari, Grace Ulerio, Julian Mackay-Wiggan, Charlotte Clark, Jane E. Cerise, Megan Furniss, Nhan Nguyen
Publikováno v: JCI insight. 1(15)
BACKGROUND. Alopecia areata (AA) is a common autoimmune disease with a lifetime risk of 1.7%; there are no FDA-approved treatments for AA. We previously identified a dominant IFN-γ transcriptional signature in cytotoxic T lymphocytes (CTLs) in human
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad026db0e08adacd8b8cda13c1f31db3
https://pubmed.ncbi.nlm.nih.gov/27699253
Zobrazit plný text záznamu
4
Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Autor: Jean Y. Tang, Ervin H. Epstein, Melika Rezaee, Michelle Aszterbaum, David R. Bickers, Anita M. Chanana, Mina S. Ally, Joselyn Lindgren, Charlotte Clark, Jackleen Marji, Ginny Gildengorin, Grace Ulerio, Julian Mackay-Wiggan
Publikováno v: The Lancet. Oncology. 17(12)
Aberrant hedgehog signalling underlies the development of basal-cell carcinomas. We previously reported the interim analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial in patients with the basal-cell nevus (Gorlin)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2032075e8855a4539199555334ab4595
https://pubmed.ncbi.nlm.nih.gov/27838223
Zobrazit plný text záznamu
6
The use of vismodegib to shrink keratocystic odontogenic tumors in patients with basal cell nevus syndrome
Autor: Jean Y. Tang, Anita M. Chanana, Ervin H. Epstein, Bobbye J. Thompson, Julian Mackay-Wiggan, Maria Acosta Raphael, David R. Bickers, Timmy Joseph, Joselyn Lindgren, Mina S. Ally, Grace Ulerio
Publikováno v: JAMA dermatology. 150(5)
Importance Keratocystic odontogenic tumors (KCOTs) of the jaw affect more than 65% of patients with basal cell nevus syndrome (BCNS). Surgery frequently causes facial disfigurement and is not always curative. Most BCNS-related and some sporadic KCOTs
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53c2a14d1669eb1e44c5482703ee3873
https://pubmed.ncbi.nlm.nih.gov/24623282
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje